Efficacy, Safety, and Strategies for Recombinant-Activated Factor VII in Cardiac Surgical Bleeding: A Narrative Review

Kidd, Brent; Sutherland, Lauren; Jabaley, Craig S.; Flynn, Brigid C.

doi:10.1053/j.jvca.2021.03.021

Cited by 2 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Recombinant factor VIIa is often recommended for severe and/or persistent bleeding after cardiac surgery, though optimal timing remains unclear. 13 A recent retrospective study has suggested that early administration of recombinant factor VIIa is associated with shorter duration of intensive care, decreased incidence of acute kidney injury, and perhaps fewer allogeneic transfusions, with no significant difference in thrombosis incidence. 14 This is in contrast to earlier studies identifying thromboembolic complications attributable to factor VIIa administration; thus it cases-anesthesia-analgesia.org…”

Section: Discussionmentioning

confidence: 99%

Undiagnosed Factor VII Deficiency in Cardiac Surgery Complicated by Bleeding: A Case Report

Knio,

Ising,

Yount

et al. 2023

A&A Practice

View full text Add to dashboard Cite

Rare bleeding disorders in the perioperative period call for targeted resuscitation strategies. Factor VII deficiency, for instance, is often corrected with exogenous administration of recombinant factor VIIa. This activated clotting factor, initially designed for patients with hemophilia A or B with factor inhibitors, is gaining popularity as a salvage therapy for severe and persistent traumatic and surgical bleeding. This article describes the management of a cardiothoracic surgical patient with undiagnosed isolated factor VII deficiency who experienced significant postoperative bleeding which subsided after the administration of recombinant factor VIIa. In this case, EXTEM failed to detect a clotting factor deficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Undiagnosed Factor VII Deficiency in Cardiac Surgery Complicated by Bleeding: A Case Report

Knio,

Ising,

Yount

et al. 2023

A&A Practice

View full text Add to dashboard Cite

show abstract

“…7,8 Up to 30% of all allogeneic blood transfusions are given to cardiac surgical patients. 9 Perioperative bleeding management includes surgical local control as well as normalization of patient temperature, pH, and calcium concentration. Correction of numerous hemostatic defects induced by cardiopulmonary bypass (CPB) and common in cardiac surgery, including hemodilution, thrombocytopathy, hyperfibrinolysis, heparin rebound, protamine overdose, and coagulation zymogen deficiency, is also necessary for hemostasis.…”

Section: Overview Of Bleeding In Cardiothoracic Surgerymentioning

confidence: 99%

Off-label Use of Recombinant Activated Factor VII for Cardiac Surgical Bleeding

2023

View full text Add to dashboard Cite

Recombinant activated factor VII has been widely used in an off-label manner for cardiac surgical bleeding. Recent reports have administered recombinant activated factor VII earlier in the course of bleeding and at lower doses than initially reported. This review will discuss the history, mechanism, current recommendations for use, and recent data on the use of recombinant activated factor VII in cardiac surgical bleeding.

show abstract

Efficacy, Safety, and Strategies for Recombinant-Activated Factor VII in Cardiac Surgical Bleeding: A Narrative Review

Cited by 2 publications

References 58 publications

Undiagnosed Factor VII Deficiency in Cardiac Surgery Complicated by Bleeding: A Case Report

Undiagnosed Factor VII Deficiency in Cardiac Surgery Complicated by Bleeding: A Case Report

Off-label Use of Recombinant Activated Factor VII for Cardiac Surgical Bleeding

Contact Info

Product

Resources

About